Cargando…
A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma
PURPOSE: We aimed to create a novel prognostic score, the inflammation-based prognosis score (IBPS). In addition, we attempted to establish and validate a nomogram to predict the overall survival (OS) of patients with DLBCL. PATIENTS AND METHODS: We retrospectively investigated the data of 213 patie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351597/ https://www.ncbi.nlm.nih.gov/pubmed/37465083 http://dx.doi.org/10.2147/CMAR.S408100 |
_version_ | 1785074363752513536 |
---|---|
author | Liu, Yajiao Sheng, Li Hua, Haiying Zhou, Jingfen Zhao, Ying Wang, Bei |
author_facet | Liu, Yajiao Sheng, Li Hua, Haiying Zhou, Jingfen Zhao, Ying Wang, Bei |
author_sort | Liu, Yajiao |
collection | PubMed |
description | PURPOSE: We aimed to create a novel prognostic score, the inflammation-based prognosis score (IBPS). In addition, we attempted to establish and validate a nomogram to predict the overall survival (OS) of patients with DLBCL. PATIENTS AND METHODS: We retrospectively investigated the data of 213 patients with DLBCL diagnosed and treated in the Affiliated Hospital of Jiangnan University and used these data to develop nomograms. At the same time, 89 patients diagnosed and treated in Wuxi People’s Hospital Affiliated with Nanjing Medical University from January 2015 to June 2021 were collected as an external validation cohort. We developed IBPS through the least absolute shrinkage and selection operator (LASSO) Cox regression. The univariate and multivariate Cox regression method was used to develop the nomogram. We used the concordance index (C-index), calibration chart, time-dependent receiver operating characteristic (ROC) analysis, decision curve analysis (DCA), and the Kaplan–Meier curve were used to assess the nomogram. RESULTS: The systemic immune inflammation index (SII), prognostic nutrition index (PNI), and modified Glasgow prognostic score (mGPS) were used to construct IBPS. The Eastern Cooperative Oncology Group performance status (ECOG PS), IBPS, response to treatment, and whether accept surgery were used to construct the nomogram to predict the OS of DLBCL patients. The C-index in the training and validation cohorts were 0.844 and 0.828, respectively. According to the time-dependent ROC curve and DCA, the nomogram has good predictive accuracy and clinical net benefit. The Kaplan–Meier curve showed that according to the nomogram score, patients in the training and validation cohorts could be classified into three risk groups. CONCLUSION: In patients with DLBCL, baseline IBPS was a reliable predictor of OS. The survival probability of DLBCL patients can be precisely predicted using the prognosis nomogram based on IBPS. |
format | Online Article Text |
id | pubmed-10351597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-103515972023-07-18 A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma Liu, Yajiao Sheng, Li Hua, Haiying Zhou, Jingfen Zhao, Ying Wang, Bei Cancer Manag Res Original Research PURPOSE: We aimed to create a novel prognostic score, the inflammation-based prognosis score (IBPS). In addition, we attempted to establish and validate a nomogram to predict the overall survival (OS) of patients with DLBCL. PATIENTS AND METHODS: We retrospectively investigated the data of 213 patients with DLBCL diagnosed and treated in the Affiliated Hospital of Jiangnan University and used these data to develop nomograms. At the same time, 89 patients diagnosed and treated in Wuxi People’s Hospital Affiliated with Nanjing Medical University from January 2015 to June 2021 were collected as an external validation cohort. We developed IBPS through the least absolute shrinkage and selection operator (LASSO) Cox regression. The univariate and multivariate Cox regression method was used to develop the nomogram. We used the concordance index (C-index), calibration chart, time-dependent receiver operating characteristic (ROC) analysis, decision curve analysis (DCA), and the Kaplan–Meier curve were used to assess the nomogram. RESULTS: The systemic immune inflammation index (SII), prognostic nutrition index (PNI), and modified Glasgow prognostic score (mGPS) were used to construct IBPS. The Eastern Cooperative Oncology Group performance status (ECOG PS), IBPS, response to treatment, and whether accept surgery were used to construct the nomogram to predict the OS of DLBCL patients. The C-index in the training and validation cohorts were 0.844 and 0.828, respectively. According to the time-dependent ROC curve and DCA, the nomogram has good predictive accuracy and clinical net benefit. The Kaplan–Meier curve showed that according to the nomogram score, patients in the training and validation cohorts could be classified into three risk groups. CONCLUSION: In patients with DLBCL, baseline IBPS was a reliable predictor of OS. The survival probability of DLBCL patients can be precisely predicted using the prognosis nomogram based on IBPS. Dove 2023-07-13 /pmc/articles/PMC10351597/ /pubmed/37465083 http://dx.doi.org/10.2147/CMAR.S408100 Text en © 2023 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liu, Yajiao Sheng, Li Hua, Haiying Zhou, Jingfen Zhao, Ying Wang, Bei A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma |
title | A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma |
title_full | A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma |
title_fullStr | A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma |
title_full_unstemmed | A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma |
title_short | A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma |
title_sort | novel and validated inflammation-based prognosis score (ibps) predicts outcomes in patients with diffuse large b-cell lymphoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351597/ https://www.ncbi.nlm.nih.gov/pubmed/37465083 http://dx.doi.org/10.2147/CMAR.S408100 |
work_keys_str_mv | AT liuyajiao anovelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT shengli anovelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT huahaiying anovelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT zhoujingfen anovelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT zhaoying anovelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT wangbei anovelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT liuyajiao novelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT shengli novelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT huahaiying novelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT zhoujingfen novelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT zhaoying novelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma AT wangbei novelandvalidatedinflammationbasedprognosisscoreibpspredictsoutcomesinpatientswithdiffuselargebcelllymphoma |